Search

Displaying results 3231 - 3240 of 10000 in total
  1. Drug

    Spirapril

    go.drugbank.com/drugs/DB01348
    ApprovedInvestigational

    ACE inhibitors are used primarily in treatment of hypertension and congestive heart failure. … Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration.

    Categories: Agents Acting on the Renin-Angiotensin System
  2. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.

    Synonyms: N,2-Dimethyl-2-phenylsuccinimide, alpha-Methyl-alpha-phenyl N-methyl succinimide
  3. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  4. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    It was granted Fast Track status for this indication by the FDA in November 2004.

  5. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    [A198771,A198777,A193800] Camostat mesylate was first approved in Japan in January 2006.[L13197] … [A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice.

  6. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    infants through six months of age. … [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023.

  7. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. … Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors.

  8. Drug

    HMI-204

    go.drugbank.com/drugs/DB18338
    Experimental

    HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A

  9. Drug

    Cyclothiazide

    go.drugbank.com/drugs/DB00606
    Approved

    This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. … As a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water.

  10. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the